You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Inflammatory Diseases
US FDA has Granted Priority Review of the Teprotumumab Biologics License Application for the Treatment of Active Thyroid Eye Disease
Login
Username:

Password:


Related Headlines

Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand

Merck and Mayo Clinic launch AI-driven drug discovery collaboration

Palisade Bio makes Clinical Advisory Board appointment

STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)

Hoth Therapeutics granted US patent for novel exon-skipping therapy targeting allergic diseases

DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval

Devonian reports gene expression data showing Thykamine's molecular effects in MASH model

Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris

IP Group plc portfolio company Microbiotica reports positive Phase 1b data for MB310 in ulcerative colitis

Formation Bio acquires worldwide rights to FHND5032 from CTFH

Almirall receives China approval for Seysara to treat moderate-to-severe acne

OSE Immunotherapeutics prioritises pouchitis and hidradenitis suppurativa for lusvertikimab development

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Physiomics secures new modelling contract with Numab Therapeutics

Simcere Pharmaceutical enter licence and collaboration agreement with Boehringer Ingelheim

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026